Table 4.
Group of Study | Meta-Analysis Proportion | Meta-Analysis Case-Control | |||||
---|---|---|---|---|---|---|---|
I2 | Proportion (95% CI) | N | I2 | OR (95% CI) | p | N infertility:N controls | |
Overall infertility | |||||||
Anti-TG2 | 69 | 1.6 (1.0–2.4) | 5009 | 0 * | 3.4 (1.7–6.6) | 0.0002 | 1614:1672 |
EMA | 65 | 1.3 (0.7–2.1) | 4233 | 11 | 3.0 (1.5–5.9) | 0.0024 | 1859:2859 |
Biopsy | 60 | 1.5 (0.6–2.8) | 1407 | 0 | 4.1 (1.3–13.2) | 0.0229 | 592:560 |
Idiopathic infertility | |||||||
Anti-TG2 | 71 | 1.5 (0.4–3.0) | 1366 | 0 * | 3.3 (1.4–7.7) | 0.0056 | 773:1231 |
EMA | 82 | 1.3 (0.1–3.4) | 1169 | 10 | 3.2 (1.4–7.2) | 0.009 | 1048:2543 |
Biopsy | - | - | - | - | - | - | - |
RSA | |||||||
Anti-TG2 | 69 | 2.2 (0.6–4.8) | 1046 | 0 | 4.4 (1.5–12.7) | 0.005 | 338:546 |
EMA | 76 | 1.1 (0–3.9) | 928 | 58 ** | 1.9 (0.1–25.8) | 0.63 | 230:421 |
Biopsy | - | - | - | - | - | - | - |
Only studies with sample sizes>100 individuals were included. For I2 ≥ 25%, a random model has been used. TG2: type 2 transglutaminase; EMA: antiendomisium antibodies; RSA: recurrent spontaneous abortion. * After excluding Vancikova et al. [10]; ** only two studies were included.